

Biocorp strikes €4 M deal with Sanofi for diabetes management

08 July 2019 | News | By Manbeena Chawla

Mallya is a smart sensor that turns conventional insulin pens into connected devices.



French Company Biocorp has entered into exclusive negotiations with Sanofi to use their Mallya connected device with Sanofi's integrated diabetes care platform.

Under the terms of these exclusive negotiations, BIOCORP will get an initial payment of €4 million from SANOFI to support related development activities.

Mallya is a smart sensor that turns conventional insulin pens into connected devices. Mallya records the key treatment information (selected dose, date and time of injection) and sends it to a dedicated mobile application. The app also allows the patient-user to view a summary report of doses injected over a period of time (up to 90 days). This device allows an automatic recording of the doses injected with the highest accuracy, removing the need for manual logbooks. Mallya is the only device available in its category to be labeled CE medical device, class IIb.

Eric Dessertenne, Chief Operating Officer of BIOCORP, said: "This exciting first step towards a partnership with Sanofi, one of the three largest diabetes care companies, confirms our position as the world leader in connected devices. For us, this is a result of the promises we have made to our shareholders, employees and partners since our initial public offering in 2015. We are proud to bring a breakthrough device to the market to improve the daily lives of patients with diabetes. We believe our innovative [Mallya](#) has great potential to become the standard in its class and should contribute significantly, and in a short time, to our very strong growth."